BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 25457204)

  • 1. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
    Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
    J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor promotion and inhibition by phenobarbital in livers of conditional Apc-deficient mice.
    Braeuning A; Gavrilov A; Geissler M; Wenz C; Colnot S; Templin MF; Metzger U; Römer M; Zell A; Schwarz M
    Arch Toxicol; 2016 Jun; 90(6):1481-94. PubMed ID: 26838046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salt-inducible Kinase (SIK1) regulates HCC progression and WNT/β-catenin activation.
    Qu C; He D; Lu X; Dong L; Zhu Y; Zhao Q; Jiang X; Chang P; Jiang X; Wang L; Zhang Y; Bi L; He J; Peng Y; Su J; Zhang H; Huang H; Li Y; Zhou S; Qu Y; Zhao Y; Zhang Z
    J Hepatol; 2016 May; 64(5):1076-1089. PubMed ID: 26778753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors.
    Aydinlik H; Nguyen TD; Moennikes O; Buchmann A; Schwarz M
    Oncogene; 2001 Nov; 20(53):7812-6. PubMed ID: 11753661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
    Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
    Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
    Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
    Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice.
    Awuah PK; Rhieu BH; Singh S; Misse A; Monga SP
    PLoS One; 2012; 7(6):e39771. PubMed ID: 22761897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
    Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
    J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice.
    Tao J; Zhang R; Singh S; Poddar M; Xu E; Oertel M; Chen X; Ganesh S; Abrams M; Monga SP
    Hepatology; 2017 May; 65(5):1581-1599. PubMed ID: 27981621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen.
    Rignall B; Braeuning A; Buchmann A; Schwarz M
    Carcinogenesis; 2011 Jan; 32(1):52-7. PubMed ID: 21047994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling.
    Wang W; Li S; Liu P; Sideras K; van de Werken HJG; van der Heide M; Cao W; Lavrijsen M; Peppelenbosch MP; Bruno M; Pan Q; Smits R
    Mol Cancer Res; 2019 Feb; 17(2):521-531. PubMed ID: 30257989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapies for human hepatocellular carcinoma: should we start from β-catenin inhibition?
    Calvisi DF
    J Hepatol; 2015 Feb; 62(2):257-9. PubMed ID: 25463532
    [No Abstract]   [Full Text] [Related]  

  • 17. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia.
    Suarez M I; Uribe D; Jaramillo CM; Osorio G; Perez JC; Lopez R; Hoyos S; Hainaut P; Pineau P; Navas MC
    Ann Hepatol; 2015; 14(1):64-74. PubMed ID: 25536643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
    Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Frequency of β-Catenin Mutations in Mouse Hepatocellular Carcinomas Induced by a Nongenotoxic Constitutive Androstane Receptor Agonist.
    Mattu S; Saliba C; Sulas P; Zavattari P; Perra A; Kowalik MA; Monga SP; Columbano A
    Am J Pathol; 2018 Nov; 188(11):2497-2507. PubMed ID: 30201494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations.
    Gougelet A; Sartor C; Bachelot L; Godard C; Marchiol C; Renault G; Tores F; Nitschke P; Cavard C; Terris B; Perret C; Colnot S
    Gut; 2016 Jun; 65(6):1024-34. PubMed ID: 25792709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.